Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

Earnings Preview: What to Expect From Moderna's Report

Based in Cambridge, Massachusetts, Moderna, Inc. (MRNA) is a leading biotechnology company that develops messenger RNA (mRNA) therapeutics and vaccines. It is renowned for its innovative mRNA technology platform, which was pivotal in the rapid development and distribution of its COVID-19 vaccine. With a market cap of $20.7 billion, Moderna is recognized for its groundbreaking research, commitment to addressing global health challenges, and efforts to develop a broad pipeline of mRNA-based treatments for various diseases. Moderna is scheduled to announce its fiscal Q3 earnings results before the market opens on Thursday, Nov. 7.

Ahead of the event, analysts expect MRNA to report a loss of $1.93 per share, rising 38.9%  compared to the loss of $1.39 per share in the same quarter last year. The company has consistently surpassed Wall Street’s EPS estimates in each of its last four quarterly reports. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.